2008/12/07 by Melanie Winkle, Sherien M. El-Daly, Sherien M. El‐Daly +7 · 9 citations
Agricultural and Biological Sciences · Biochemistry, Genetics and Molecular Biology · Medicine · #Banana Cultivation and Research #Bioinformatics #Biology #Cancer-related molecular mechanisms research #Citrus paradisi #Clinical trial #Computational biology #Forestry #Gene #Genetics #Geography #Horticulture #Long non-coding RNA #Medicine #MicroRNA in disease regulation #Non-coding RNA #Orchard #Plant Pathogens and Fungal Diseases #Plant Physiology and Cultivation Studies #RNA #RNA Interference and Gene Delivery #RNA interference #Rutaceae #microRNA
paper · pdf · open access · doi:10.1038/s41573-021-00219-z
published in Nature Reviews Drug Discovery 45(8), 83-85 (Nature Portfolio)
openalex publication_date 2008/12/07 · crossref issued 2021/06/18 · crossref published 2021/06/18 · crossref published-online 2021/06/18 · crossref created 2021/06/18 · crossref published-print 2021/08/01 · crossref deposited 2024/12/11 · openalex created_date 2025/10/10 · crossref indexed 2026/07/30 · openalex updated_date 2026/08/01
Therapeutic targeting of noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), represents an attractive approach for the treatment of cancers, as well as many other diseases. Over the past decade, substantial effort has been made towards the clinical application of RNA-based therapeutics, employing mostly antisense oligonucleotides and small interfering RNAs, with several gaining FDA approval. However, trial results have so far been ambivalent, with some studies reporting potent effects whereas others demonstrated limited efficacy or toxicity. Alternative entities such as antimiRNAs are undergoing clinical testing, and lncRNA-based therapeutics are gaining interest. In this Perspective, we discuss key challenges facing ncRNA therapeutics - including issues associated with specificity, delivery and tolerability - and focus on promising emerging approaches that aim to boost their success.